Bralangine

Pain syndrome with spasms of smooth muscles of internal organs (renal and biliary colic, intestinal spasm, dysmenorrhea, etc.), joint pain, neuralgia, sciatica, myalgia (short-term symptomatic treatment), pain after surgical and diagnostic interventions (auxiliary agent), fever in colds and infectious and inflammatory diseases.

Inside, single and daily doses are respectively: adults and adolescents over 15 years — 1 and 8 tables (2 tables 4 times a day), children 12-14 years (body weight not less than 50 kg) — 1 and 6 tables (1.5 tables 4 times a day), children aged 8-11 years (body weight about 33 kg) - 0.5 and 4 tables (1 table 4 times a day), children 5-7 years old (body weight about 24 kg) - 0.5 and 2 tablets (0.5 tablets 4 times a day).

V/ v, v / m. The single and maximum daily dose are, respectively: adults and adolescents over 15 years of age-2-5 ml and 10 ml (5 ml 2 times a day), intravenous administration of a single dose of more than 2 ml is possible only after careful clarification of the indications. For children and infants, the daily dose is set taking into account body weight: children 12-15 years old (body weight 46-53 kg) - in/in and in / m 0.8-1 ml, children 8-12 years old (body weight 31-45 kg) - in / in 0.5-0.6 ml and in / m 0.6-0.7 ml, children 5-7 years old (body weight 24-30 kg) — I/0,3–0,4 ml/m of 0.4–0.5 ml, children 3-4 years (body weight 16-23 kg) in/0,2–0,3 ml/m of 0.3–0.4 ml, children 1-2 years (body weight 9-15 kg) in 0.1–0.2 ml/m 0.2–0.3 ml, children 3-11 months (body weight 5-8 kg) — only in / m 0.1-0.2 ml. Intravenous administration is carried out slowly (1 ml for at least 1 min), in the patient's lying position and under the control of blood pressure, heart rate and respiratory rate. The injection solution must have a body temperature of. The solution is not compatible in the same syringe with any other medicines

Hypersensitivity, tachyarrhythmia, severe liver and kidney function disorders, bronchial asthma, blood system diseases, collaptoid conditions, congenital glucose−6-phosphate dehydrogenase deficiency, angle-closure glaucoma, mechanical gastrointestinal stenosis, megacolon, prostatic hypertrophy with a tendency to accumulate residual urine, age up to 3 months or a child's body weight less than 5 kg, pregnancy (first trimester and last 6 weeks), breast-feeding.

From the cardiovascular system and blood (hematopoiesis, hemostasis): a sharp decrease in blood pressure, agranulocytosis, leukopenia, thrombocytopenia.

From the genitourinary system: oliguria, anuria, proteinuria.

From the skin: Stevens-Johnson syndrome, Lyell syndrome.

Allergic reactions: urticaria, the lesions of the conjunctiva, the mucous membrane of the nasopharynx, anaphylactic and anaphylactoid reactions.

Other: soreness at the injection site.

In therapeutic doses, the drug is usually well tolerated.

It passes through the placental barrier and enters breast milk. It is excreted from the body by the kidneys.

• NSAIDs-Pyrazolones in combinations

Concomitant use with other non-narcotic analgesics may lead to a mutual increase in toxic effects. Tricyclic antidepressants, oral contraceptives, and allopurinol increase the toxicity of the drug. Barbiturates, phenylbutazone and other inducers of microsomal liver enzymes weaken the effect of metamizole. Concomitant use with cyclosporine lowers the level of the latter in the blood. Sedatives and tranquilizers increase the analgesic effect Palagina.

In a dry place, protected from light, at a temperature not exceeding 25 °C.

Keep out of reach of children.

Do not use after the expiration date indicated on the package.

1 tablet contains metamizole sodium (or Analgin) 0.5 g, pitofenone hydrochloride 0.005 g and fenpiverinium bromide 0.0001 g, in a contour cell package of 10 pcs. , in a cardboard pack of 1, 2 or 10 packages.

1 ampoule with 5 ml of solution for injection-metamizole sodium (or Analgin) 0.5 g, pitofenone hydrochloride 0.002 g and fenpiverinium bromide 0.00002 g, in a contour cell package of 5 ampoules, in a cardboard pack of 1 package.

It is contraindicated in the first trimester and in the last 6 weeks of pregnancy, in other periods only under strict indications and under the supervision of a doctor. Breastfeeding should be discontinued for the duration of treatment.

N02BB52 Metamizole sodium in combination with other drugs other than psycholeptics

• K80. 5 Bile duct stones without cholangitis or cholecystitis
• M54. 3 Sciatica
• M79. 1 Myalgia
• M79. 2 Neuralgia and neuritis, unspecified
• N23 Renal colic, unspecified
• N94. 6 Dysmenorrhea, unspecified
• R10. 4 Other and unspecified abdominal pain
• R25. 2 Cramp and spasm
• R30 Pain associated with urination
• R52. 9 Pain, unspecified